Sex differences in response to chronic heart failure therapies

References

• Lindenfeld J, Krause-Steinrauf H, Salernao J. Where are all the women with heart failure ? J. Am. Coll. Cardiol.30, 1417–1419 (1997).
   PubMed Web of Science ®Google Scholar
• Ghali JK. A clinicians perspective on clinical trials. J. Card. Fail.7, 1–3 (2001).
   PubMed Web of Science ®Google Scholar
• Heiat A. Gross, CP, Krumholz, HM. Representation of the elderly women, and minorities in heart failure clinical trials. Arch. Intern. Med.162, 1681–1688 (2002).
   Google Scholar
• Adams KF, Lindenfeld J, Arnold JMO et al. Executive Summary: HFSA 2006 Comprehensive HF Practice Guideline. J. Card. Fail.12, 10–38 (2006).
   PubMed Web of Science ®Google Scholar
• Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/AmericanHeart Association Task Force on Practice Guidelines. Writing Committee to Update the Guidelines for the Evaluation and Management of Heart Failure. Circulation112, e154–e235 (2005).
   PubMed Web of Science ®Google Scholar
• Swedberg K, Cleland J, Dargie H et al. Task force for the diagnosis and treatment of chronic heart failure of the european society of cardiology. Eur. Heart J.26, 1115–1140 (2005).
   PubMed Web of Science ®Google Scholar
• NIH Guide 23(11) (1994).
   Google Scholar
• Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N. Engl. J. Med.314, 1547–1552 (1986).
   PubMed Web of Science ®Google Scholar
• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med.316, 1429–1435 (1987).
   Google Scholar
• Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med.325, 303–310 (1991).
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med.325, 293–302 (1991).
   Google Scholar
• The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N. Engl. J. Med.327, 685–691 (1992).
   Google Scholar
• Packer M, Carver JR, Rodeheffer RJ et al. The PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N. Engl. J. Med.325, 1468–1475 (1991).
   PubMed Web of Science ®Google Scholar
• Singh SN, Fletcher RD, Fisher SG et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure. N. Engl. J. Med.333, 77–82 (1995).
   PubMed Web of Science ®Google Scholar
• Packer M, O’Connor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective randomized amlodipine survival evaluation study group. N. Engl. J. Med.335, 1107–1114 (1996).
   PubMed Web of Science ®Google Scholar
• Califf RM, Adams KF, McKenna WJ et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure. The Flolan International Randomized Survivial Trial (FIRST). Am. Heart J.134, 44–54 (1997).
   PubMed Web of Science ®Google Scholar
• Hampton JR, van Veldhuisen DJ, Kleber FX et al. Randomized study of effect of ibopamine on survival in patients with advanced severe heart failure. Second prospective randomized study of Ibopamine on mortality and efficacy (PRIME II) investigators. Lancet349, 971–977 (1997).
   PubMed Web of Science ®Google Scholar
• The Digitalis Investigation Group. The effects of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med.336, 525–533 (1997).
   Google Scholar
• Pitt B, Segal R, Martinez FA et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure. (Evaluation of Losartan in the Elderly Study, ELITE). Lancet349, 747–752 (1997).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Goldstein SO, Greenberg BH et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N. Engl. J. Med.339, 1810–1816 (1998).
   PubMed Web of Science ®Google Scholar
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. Lancet353, 9–13 (1999).
   Google Scholar
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestion Heart Failure (MERIT-HF). Lancet353, 2001–2007 (1999).
   Google Scholar
• Packer M, Poole-Wilson PA, Armstrong PW et al. Comparitive effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation100, 2312–2318 (1999).
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N. Engl. J. Med.341, 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial: the losartan heart failure survival study ELITE II. Lancet355, 582–1587 (2000).
   Google Scholar
• β-Blocker Evaluation of Survival Trial Investigators. A trial of the β-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med.344, 1659–1667 (2001).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N. Engl. J. Med.345, 1667–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Packer M, Fowler MD, Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prosepctive randomized cumulative survival (COPERNICUS) study. Circulation106, 2194–2199 (2002).
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JGF et al. Carvedilol or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): randomized controlled trial. Lancet362, 7–13 (2003).
   PubMed Web of Science ®Google Scholar
• McMurray J, Ostergren J, Pfeffer M et al. CHARM committees and investigators. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM) programme. Eur. J. Heart Fail.5, 261–270 (2003).
   PubMed Web of Science ®Google Scholar
• Bristow MR, Saxon LA, Boehmer J et al. Comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med.350, 2140–2150 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med.351, 2049–2057 (2004).
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med.352, 225–237 (2005).
   PubMed Web of Science ®Google Scholar
• Cleland JGF, Daubert JD, Erdmann E, Freemantle N, Gras D et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med.352, 1539–1549 (2005).
   PubMed Web of Science ®Google Scholar
• Ghali, JK. Sex related differences in heart failure. In: Managing Acute Decompensated Heart Failure. O’Conner et al. (Ed.). Taylor & Francis, Boca Raton, Fl, USA 53–70 (2005).
   Google Scholar
• Ho KK, Pinsky JL, Kannel WB et al. The epidemiology of heart failure: the Framingham Study. J. Am. Coll. Cardiol.22(4 Suppl. A), 6A–13A (1993).
   PubMedGoogle Scholar
• Thom T, Haase N, Rosamond W et al. American Heart Association Statistics Committee and Stroke Statistics SubcommitteeHeart disease and stroke statistics – 2006 update: a report from the AmericanHeart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation113(6), e85–e151. (2006).
   PubMed Web of Science ®Google Scholar
• Senni M, Tribouilloy CM, Rodeheffer RJ et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation98, 2282 (1998).
   PubMed Web of Science ®Google Scholar
• Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J. Am. Coll. Cardiol.33, 1948–1955 (1999).
   PubMed Web of Science ®Google Scholar
• Lindenfeld J, Fiske KS, Stevens BR et al. Age, but not sex, influences the measurement of ejection fraction in elderly patients hospitalized for heart failure. J. Card. Fail.9, 100–106 (2003).
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Exploring the Biological Contributions to Human Health: Does Sex Matter? National Academy Press, Washington, DC, USA (2001).
   Google Scholar
• Konhilas JP, Leinwand LA. The effects of biological sex and diet on the development of heart failure. Circulation116, 2747–2759 (2007).
   PubMed Web of Science ®Google Scholar
• van Eickels M, Grohé C, Cleutjens JP, Janssen BJ, Wellens HJ, Doevendans PA.17β-estradiol attenuates the development of pressure-overload hypertrophy. Circulation104, 1419–1423 (2001).
   PubMed Web of Science ®Google Scholar
• Cavasin MA, Sankey SS, Yu AL, Menon S, Yang XP. Estrogen and testosterone have opposing effects on chronic cardiac remodeling andfunction in mice with myocardial infarction. Am. J. Physiol. Heart Circ. Physiol.284, H1560–H1569 (2003).
   PubMed Web of Science ®Google Scholar
• Hayward CS, Webb CM, Collins P. Effect of sex hormones on cardiac mass. Lancet357(9265), 1354–1356 (2001).
   PubMed Web of Science ®Google Scholar
• Douglas PS, Otto CM, Mickel MC et al. Gender differences in left ventricle geometry and function in patients undergoing balloon dilatation of the aortic valve for isolated aortic stenosis. NHLBI Balloon Valvuloplasty Registry. Br. Heart J.73, 548–554 (1995).
   PubMedGoogle Scholar
• Gerdes AM, Onodera T, Wang X et al. Myocyte remodeling during the progression to failure in rats with hypertension. Hypertension28, 609–614 (1996).
   PubMed Web of Science ®Google Scholar
• Douglas PS, Katz SE, Weinberg EO et al. Hypertrophic remodeling: gender differences in the early response to leftventricular pressure overload. J. Am. Coll. Cardiol.32, 1118–1125 (1998).
   PubMed Web of Science ®Google Scholar
• Tamura T, Said S, Gerdes AM. Gender-related differences in myocyte remodeling in progression to heart failure. Hypertension33, 676–680 (1999).
   PubMed Web of Science ®Google Scholar
• Ghali JK, Crause-Steinrauf HJ, Adams KF et al. Gender difference in advanced heart failure ; insights from the BEST study. J. Am. Coll. Cardiol.42, 2128–2134 (2003).
   PubMed Web of Science ®Google Scholar
• Simon T, Mary-Drause M, Funck-Brentano C et al. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation103, 375–380 (2001).
   PubMed Web of Science ®Google Scholar
• Ghali JK, Pina IL, Gottlief SS et al. MERIT-HF Study Troup, Metoprolol CR/XL in female patients with heart failure: analysis of the experience in metoprolol extended-release randomized intervention trial in heart failure (MERIT-HF). Circulation105, 1585–1591 (2002).
   PubMed Web of Science ®Google Scholar
• O’Meara E, Clayton T, McEntegart MB et al. CHARM Investigators. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation115(24), 3111–3120 (2007).
   PubMed Web of Science ®Google Scholar
• Aronson D, Burger AJ. Gender-related differences in modulation of heart rate in patients with congestive heart failure. J. Cardiovasc. Electrophysiol.11, 1071–1077 (2000).
   PubMed Web of Science ®Google Scholar
• Adams KF Jr, Dunlap SH, Sueta Ca et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J. Am. Coll. Cardiol.28, 1781–1788 (1996).
   PubMed Web of Science ®Google Scholar
• Adams KF Jr, Sueta CA, Gheorghiade M et al. Gender differences in survival in advanced heart failure. Insights from the FIRST study. Circulation99, 1816–1821 (1999).
   PubMed Web of Science ®Google Scholar
• Opasich C, De Giuli F, Majani G et al. Heart failure woman: does she make any difference? Ital. Heart J.4, 4–16 (2003).
   PubMedGoogle Scholar
• Taylor AL, Lindenfeld JA, Ziesche S et al. Outcomes by gender in the African-American heart failure trial. J. Am. Coll. Cardiol.48, 2263–2267 (2006).
   PubMed Web of Science ®Google Scholar
• Johnstone D, Limacher M, Rousseau M et al. Clinical characteristics of patients in studies of left ventricular dysfunction (SOLVD). Am. J. Cardiol.70, 894–900 (1992).
   PubMed Web of Science ®Google Scholar
• Majahalme SK, Baruch L, Aknay N et al. Comparison of treatment benefit and outcome on women vs men with chronic heart failure (from the Valsartan Heart Failure Trial). Am. J. Cardiol.95, 529–532 (2005).
   PubMed Web of Science ®Google Scholar
• Fisher LD, Kennedy JW, Davis KB et al. Association of sex, physical size, and operative mortality after coronary artery bypass in the Coronary Artery Surgery Study (CASS). J. Thorac. Cardiovasc. Surg.84, 334–341 (1982).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K et al. CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet362, 777–81 (2003).
   PubMed Web of Science ®Google Scholar
• Cleland JG, Tendera M, Adamus J et al. PEP-CHF Investigators.The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur. Heart J.27, 2338–2345 (2006).
   PubMed Web of Science ®Google Scholar
• Limacher MC, Yusef S. SOLVD Investigators. Gender differences in presentation, morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD); a preliminary report. In: Cardiovascular Health and Disease in Women. Wenger NK, Speroff L, Packard B (Eds). LeJacq Communicatons, Greenwich, CT, USA 345–348 (1993).
   Google Scholar
• Garg R, Yusuf S, for the collaborative group on ACE inhibitor trials. overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA273, 1450–1456 (1995).
   PubMed Web of Science ®Google Scholar
• Shekelle PG, Rich MW, Morton SC et al. Efficacy of angiotensin-converting enzyme inhibitors and b blockers in the management of left ventricular systolic dysfunction according to race, gender and diabetic status- a meta-analysis of major clinical trials. J. Am. Coll. Cardiol.41, 1529–1538 (2003).
   PubMed Web of Science ®Google Scholar
• Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure of left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardiol Infarction Collaborative Group. Lancet355, 1575–1581 (2000).
   PubMed Web of Science ®Google Scholar
• Keyhan G, Chen SF, Pilote L. Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure. Eur. J. Heart Fail.9, 596–601 (2007).
   Google Scholar
• Hudson M, Rahme E, Behlouli H et al. Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure-A population study. Eur. J. Heart Fail.9, 602–609 (2007).
   PubMed Web of Science ®Google Scholar
• Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardivascular system. Cardiovasc. Res.53, 672–677 (2002).
   PubMed Web of Science ®Google Scholar
• Roesch DM, Tian Y, Zheng W et al. Estradiol attenuates angiotensin-induced aldosterone secretion in ovariectomized rats. Endocrinology141, 4629–4636 (2000).
   PubMed Web of Science ®Google Scholar
• Nickenig G, Baumer AT, Grohe C et al. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation97, 2197–2201 (1998).
   PubMed Web of Science ®Google Scholar
• Radin JM, Holycross BJ, Sharkey LC et al. Gender modulates activation of renin–antiotensin and endothelin systems in hypertension and heart failure. J. Appl. Physiol.92, 935–940 (2002).
   PubMed Web of Science ®Google Scholar
• Tipnis SR, Hooper NM, Hyde R et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem.275, 33238–33243 (2000).
   PubMed Web of Science ®Google Scholar
• Donoghue M, Hsieh F, Baronas E et al. A novel angiotensin-converting enzyme-related carboxypeptide (ACE2) converts angio-tensin I to angiotensin 1–9. Circ. Res.87, E1–E9 (2000).
   PubMed Web of Science ®Google Scholar
• Crackower MA, Sarao R, Oudie GY et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature417, 822–828 (2002).
   PubMed Web of Science ®Google Scholar
• Danilczyk U, Eriksson U, Crackower MA et al. A story of two ACE’s. J. Mol. Med.81, 227–234 (2003).
   PubMed Web of Science ®Google Scholar
• Kostis JB, Shelton B, Gosselin G et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am. Heart J.131, 350–355 (1996).
   PubMed Web of Science ®Google Scholar
• Keyhan G, Chen SF, Pilote L. The effectiveness of β-blockers in women with congestive heart failure. J. Gen. Intern. Med.22(7), 955–961 (2007).
   PubMed Web of Science ®Google Scholar
• Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N. Engl. J. Med.347, 1403–1411. (2002).
   PubMed Web of Science ®Google Scholar
• Adams KF Jr, Patterson JH, Gattis WA et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial; a retrospective analysis. J. Am. Coll. Cardiol.46, 497–504 (2005).
   PubMed Web of Science ®Google Scholar
• Domanski M, Fleg J, Bristow M, Knox S. The effect of gender on outcome in digitalis-treated heart failure patients. J. Card. Fail.1, 83–86 (2005).
   Google Scholar
• Stevenson LW, Rose EA. Left ventricular assist devices: bridges to transplantation, recovery, and destination for whom? Circulation108(25), 3059–3063 (2003).
   PubMed Web of Science ®Google Scholar
• Lietz K, Long JW, Kfoury AG et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation116, 497–505 (2007).
   PubMed Web of Science ®Google Scholar
• Miller LW, Pagani FD, Russell SD et al. HeartMate II Clinical Investigators. Use of a continuous-flow device in patients awaiting heart transplantation. N. Engl. J. Med.357, 885–896 (2007).
   PubMed Web of Science ®Google Scholar
• Taylor DO, Edwards LB, Boucek MM et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report. J. Heart Lung Transplant.26, 769–781 (2007).
   PubMed Web of Science ®Google Scholar
• Morimoto T, Gandhi TK, Fiskio JM et al. Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough. J. Gen. Intern. Med.19, 684–91 (2004).
   PubMed Web of Science ®Google Scholar
• Baris N, Kalkan S, Güneri S et al. Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? Eur. J. Clin. Pharmacol.62, 535–538 (2006).
   PubMed Web of Science ®Google Scholar
• Essebag V, Hadjis T, Platt RW et al. Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. J. Am. Coll. Cardiol.5 (41), 249–254 (2003).
   Google Scholar
• Essebag V, Reynolds MR, Hadjis T et al. Sex differences in the relationship between amiodarone use and the need for permanent pacing in patients with atrial fibrillation. Arch. Intern. Med.16, 71648–71653 (2007).
   Google Scholar
• Laird R, Weiss SO, Lindenfeld J. The Female patient. Heart Fail. Women23, 46–55 (2005).
   Google Scholar
• Pfeffer MA, Braunwald E, Moye LA et al.; The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N. Engl. J. Med.327, 669–677 (1999).
   Google Scholar
• Ambrosioni E, Borghi C, Magnani B; The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N. Engl. J. Med.332, 80–85 (1995).
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, Carlsen JE et al.; Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med.333, 1670–1676 (1995).
   PubMed Web of Science ®Google Scholar
• Ghali JK. Sex related differences in heart failure and β-blockers. Heart Fail. Rev.9, 149–159 (2004).
   PubMed Web of Science ®Google Scholar